Standout Papers

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorec... 2004 2026 2011 2018 3.8k
  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer (2004)
    David Cunningham, Yves Humblet et al. New England Journal of Medicine
  2. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
    Arndt Vogel, Andrés Cervantes et al. Annals of Oncology
  3. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis (2016)
    Mustafa Suker, Berend R. Beumer et al. The Lancet Oncology
  4. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial (2015)
    Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology
  5. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer (2009)
    David Cunningham, Ian Chau et al. Journal of Clinical Oncology
  6. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial (2013)
    Thomas K. Waddell, Ian Chau et al. The Lancet Oncology
  7. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018)
    Yelena Y. Janjigian, Johanna C. Bendell et al. Journal of Clinical Oncology
  8. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial (2013)
    Hugo Ford, Andrea Marshall et al. The Lancet Oncology
  9. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines (2021)
    Arndt Vogel, Erika Martinelli et al. Annals of Oncology
  10. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study (2023)
    Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 3 from Science/Nature 154 standout
Sub-graph 1 of 16

Citing Papers

Pancreatic cancer
2025 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
26 intermediate papers

Works of Ian Chau being referenced

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
2018
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Ian Chau 12763 6982 5277 463 18.2k
Valérie Boige 9238 6005 5539 282 17.2k
Marc Ychou 15774 7558 4736 319 21.6k
Andrés Cervantes 17546 9130 8193 459 26.9k
Olivier Bouché 18148 9242 7789 410 24.6k
Dirk Arnold 11020 6501 6756 265 16.5k
Stefano Cascinu 10996 7058 3304 643 17.8k
Joon Oh Park 9002 7439 4256 378 15.8k
Jinru Shia 12327 3852 6614 367 18.5k
Christophe Louvet 14592 5964 4101 278 17.4k
Steven R. Alberts 12210 5103 4512 308 16.8k

All Works

Loading papers...

Rankless by CCL
2026